News

Clinical Trials Arena12h
Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001
Adicet Bio has dosed the first systemic sclerosis (SSc) subject in the Phase I trial’s second cohort evaluating ADI-001.
Clinical Trials Arena13h
Memo advances kidney transplant infection drug despite Phase II miss
Memo Therapeutics will discuss the Phase III trial design for potravitug in kidney transplant infection with regulators by the end of 2025.
Clinical Trials Arena15h
First subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525
Vir Biotechnology has dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-masked TCE.